Latest GLMD reports update at 2024-05-14: 2023 ∙ 2022 ∙ 2021

Galmed Pharmaceuticals Ltd. GLMD

$ 0.42 6.71%

Galmed Pharmaceuticals Ltd. Balance Sheet 2011-2024 | GLMD

Annual Balance Sheet Galmed Pharmaceuticals Ltd.

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-	-	-3.1 M	-4.16 M	-23.7 M	-137 K	1.13 M	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	1.82 M	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	44 K	229 K	216 K	352 K	-	-	796 K	177 K	400 K	428 K	2.23 M	-
Total Current Liabilities	2.75 M	3.09 M	5.88 M	8.01 M	6.93 M	2.71 M	3.85 M	4.58 M	2.54 M	1.12 M	-	-	-
Total Liabilities	-	-	-	8.23 M	7.29 M	2.71 M	3.85 M	5.38 M	2.72 M	1.52 M	2.12 M	2.74 M	-
Deferred Revenue	-	-	-	-	-	-	538 K	1.09 M	-	-	-	-	-
Retained Earnings	-193 M	-186 M	-168 M	-136 M	-107 M	-86.5 M	-76.6 M	-64.3 M	-47.4 M	-36.7 M	-27.6 M	-10.2 M	-
Total Assets	16.6 M	16.6 M	36.6 M	52.4 M	77.1 M	90.6 M	19.6 M	16.4 M	24.3 M	32.9 M	166 K	762 K	-
Cash and Cash Equivalents	-	-	-	6.95 M	15.9 M	24.2 M	13 M	3.1 M	4.16 M	23.7 M	137 K	718 K	-
Book Value	-	-	36.6 M	44.2 M	69.9 M	87.9 M	15.8 M	11.1 M	21.5 M	31.4 M	-1.95 M	-1.98 M	-
Total Shareholders Equity	13.9 M	13.4 M	30.5 M	44.2 M	69.9 M	87.9 M	15.8 M	11.1 M	21.5 M	31.4 M	-1.95 M	-	-

All numbers in USD currency

Quarterly Balance Sheet Galmed Pharmaceuticals Ltd.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	229 K	-	318 K	-	216 K	-	251 K	-	352 K	-	-	-	-	-	-	-	-	-	150 K	-	796 K	-	222 K	-	177 K	-	-	-	400 K	-	-	-	428 K	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	229 K	-	318 K	-	216 K	-	251 K	-	352 K	-	442 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	538 K	-	1.08 M	-	1.09 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-168 M	-	-153 M	-	-136 M	-	-119 M	-	-107 M	-	-94.1 M	-	-86.5 M	-	-81.8 M	-	-76.6 M	-	-70.2 M	-	-64.3 M	-	-55.7 M	-	-47.4 M	-	-	-	-36.7 M	-	-	-	-27.6 M	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	-	36.6 M	-	52.3 M	-	52.4 M	-	64.8 M	-	77.1 M	-	85.1 M	-	90.6 M	-	94.8 M	-	19.6 M	-	10 M	-	16.4 M	-	18 M	-	24.3 M	-	-	-	32.9 M	-	-	-	166 K	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	-	2.88 M	-	7.92 M	-	6.95 M	-	5.55 M	-	15.9 M	-	25.8 M	-	24.2 M	-	6.15 M	-	13 M	-	1.75 M	-	3.1 M	-	2.95 M	-	4.16 M	-	7.32 M	-	23.7 M	-	-	-	137 K	-	-	-	718 K	-	-	-	146 K	-	-	-
Book Value	-	-	-	-	36.6 M	-	52.3 M	-	52.4 M	-	64.8 M	-	77.1 M	-	85.1 M	-	90.6 M	-	94.8 M	-	19.6 M	-	10 M	-	16.4 M	-	18 M	-	24.3 M	-	-	-	32.9 M	-	-	-	166 K	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-	30.5 M	-	45 M	53 M	44.2 M	-	59.9 M	64.1 M	69.9 M	-	81.4 M	84.9 M	87.9 M	-	91 M	13.6 M	15.8 M	-	6.24 M	-	11.1 M	-	14.4 M	-	21.5 M	-	-	-	31.4 M	-	-	-	-1.95 M	-	-	-	-1.98 M	-	-	-	-2.71 M	-	-	-

All numbers in USD currency